Jun 30 2012
"Research funded by the Dengue Vaccine Initiative (DVI) involving an economic analysis of producing a tetravalent dengue vaccine shows that the cost could be as low as $0.20 per dose with an annual production level of 60 million doses packaged in 10-dose vials," a Sabin Vaccine Institute press release reports. The study, published in the July 6 issue of the journal Vaccine, "used data on a vaccine developed by U.S. NIH and the facilities of the Instituto Butantan in Sao Paulo, Brazil," the press release notes, adding the findings "should provide confidence to ministries of health that they can aggressively plan for the inclusion of dengue vaccine in their immunization programs, as the vaccine should be available at a cost that even middle-income and developing countries can afford" (6/27).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente. |